 |
|
|
| |
HIGH EFFICACY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1b INFECTION TREATED WITH ELBASVIR/GRAZOPREVIR FOR 12 WEEKS: AN INTEGRATED ANALYSIS
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
Jacob George1, Stefan Zeuzem2, Lawrence Serfaty3, John Vierling4, Wendy Cheng5, Jan Sperl6, Simone Strasser7, Hiromitsu Kumada8, Peggy Hwang9 Michael Robertson9, Janice Wahl9, Eliav Barr9, Rohit Talwani9, Heather Platt9
1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia; 2Goethe University Hospital, Frankfurt, Germany; 3Universite Pierre & Marie Curie, Paris, France; 4Baylor College of Medicine, Baylor-St. Luke's Medical Center, Houston, Texas; 5Royal Perth Hospital, Perth, WA, Australia; 6Institut Klinicke a Experiment‡lni Mediciny (IKEM), Prague, Czech Republic; 7AW Morrow Gastroenterology and Liver Centre, Sydney, NSW, Australia; 8Department of Hepatology, Toranomon Hospital, Tokyo, Japan; 9Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
